ANN ARBOR �?? HandyLab has signed an exclusive agreement to co-market its molecular assays on BD Diagnostics’s new Max system, an automated molecular diasgnostic testing platform in development using HandyLab’s recently launched Jaguar instrument.
BD will focus initially on its BD GeneOhm line of molecular assays to detect major pathogens associated with healthcare-associated infections.
“This collaboration further demonstrates BD�??s commitment to address underappreciated healthcare needs,” said Philippe Jacon, President, BD Diagnostics �?? Diagnostic Systems. “As our customers expand their HAI and sexually transmitted infection testing programs, they are seeking simple, flexible and fully automated systems to meet their increasing demands. Our new BD MAX system will be a good strategic fit with our current platforms and those under development.”
Released by HandyLab in November 2008, the Jaguar system is the first fully integrated bench-top molecular diagnostic system to provide hands-off operation. The system incorporates clinical sample preparation, nucleic acid extraction, and microfluidic real-time polymerase chain reaction (PCR) amplification and detection. The self-contained workstation is designed to accommodate on-demand and batch workflows. It requires minimal laboratory space and minimal skill levels to generate up to 24 real-time PCR results in under two hours.
“This exclusive collaboration with BD represents an important step forward in expanding the utility of the Jaguar system,” said Jeff Williams, President and CEO, HandyLab. “BD is a global leader in molecular diagnostic testing for infectious diseases. Together we plan to provide diagnostic laboratories with a broad molecular test menu on one of the industry�??s most advanced automation platform.”
BD is a leader in rapid molecular test methods to help detect major HAI-associated pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, vancomycin-resistant enterococcus and toxigenic Clostridium difficile. The BD GeneOhm MRSA assay has been used to test over 4 million patients worldwide for carriage of the potentially lethal MRSA bacteria. BD is also a leader in molecular testing for Chlamydia and gonorrhea with its BD ProbeTec Chlamydia trachomatis (CT) Amplified DNA Assay and the BD ProbeTec Neisseria gonorrhoeae (GC) Amplified DNA Assay.
HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products. HandyLab�??s proprietary platform reduces the time, cost and complexity of testing while improving the quality of results. Using patented real time microfluidic PCR technology, HandyLab’s products are positioned to decentralize nucleic acid testing. HandyLab is an Ann Arbor, Michigan based company.
For more information, click on HandyLab.Com
a>>
